Combination chemotherapy as single modality therapy for stage IE and IIE thyroid lymphoma

P. J. Leedman, W. P. Sheridan, W. F. Downey, R. M. Fox, F. I.R. Martin

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Three women presented with malignant thyroid lymphoma (stage IE and IIE) that was associated with Hashimoto's thyroiditis. Each patient was treated with combination chemotherapy (two patients received cyclophosphamide/adriamycin/vincristine/prednisolone, one patient received methotrexate/adriamycin/cyclophosphamide/vincristine/prednisolone/bleo mycin) as the primary mode of therapy. One patient underwent incomplete excisional surgery and received chemotherapy. A complete clinical and radiological remission was achieved in all patients, in spite of evidence of extensive extrathyroidal invasion in two patients. The chemotherapy was well-tolerated, producing minimal toxicity. All the patients are alive and remain free of tumour recurrence 26 to more than 38 months after diagnosis. These results suggest that combination chemotherapy can be employed successfully as a single modality treatment for stage IE and IIE thyroid lymphomas, even when significant extrathyroidal invasion is present. The treatment of thyroid lymphoma is reviewed with emphasis on the potential role for chemotherapy as the primary modality.

Original languageEnglish
Pages (from-to)40-43
Number of pages4
JournalMedical Journal of Australia
Issue number1
Publication statusPublished - 1990
Externally publishedYes


Dive into the research topics of 'Combination chemotherapy as single modality therapy for stage IE and IIE thyroid lymphoma'. Together they form a unique fingerprint.

Cite this